ClinicalTrials.gg
RecruitingNCT06413823VPCUpdated May 14, 2024

Prevention and Treatment of Cardiovascular Disease

An observational study in Cardiovascular Disease, sponsored by IRCCS Centro Neurolesi Bonino Pulejo. Recruiting at 1 site in Italy. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by IRCCS Centro Neurolesi Bonino Pulejo · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
218
Ages
45 Years to 85 Years
Sex
All
01

Study summary

In view of the close interrelationship between the various organs and systems of the body, which cannot be examined in a parceled fashion but rather as an integrated system, this study aims to consider the potential risks associated with cardiovascular disease.

By identifying additional, often underestimated, altered functions that may affect the patient's quality of life and interfere with the performance of daily activities, this research study aims to evaluate the patient's functioning in an integrated manner to achieve a holistic view of the health and well-being of the patient and caregiver.

Read the detailed description

The study design is observational and is planned to last approximately 24 months. The overall duration will be related to the time required for enrollment of all planned subjects, data analysis and publication of results.

The study aims to analyze and investigate the most common comorbidities in patients with cardiovascular disease. In addition, a specific focus will be devoted to the caregiver, who plays a key role for the cardiopathic patient.

In detail, the objectives of the project are:

  1. Evaluate the connection between cardiovascular disease and cognitive deficits;
  2. Evaluate the main psychopathologies related to cardiovascular diseases (anxiety, depression);
  3. Evaluate conditions and disorders associated with cardiovascular diseases (dysphagia, pneumophonic coordination disorders, respiratory sleep disorders);
  4. Evaluate the effectiveness of psychoeducational intervention;
  5. Evaluate the impact of cardiovascular disease on the caregiver.

A minimum of 218 patients recruited from those afferent at the U.O.S.D. Cardiology with NICU P.O. "Piemonte" in Messina will participate in the survey. Statistical power analysis was performed using G*Power software for a linear regression test, assuming a slope (H1) of 0.2 with a significance level (α) of 0.05 and a power (1 - β) of 0.85. The primary outcome variable considered for the calculation is the result of the SF-12 (or SF-36) test as a summary index of the effectiveness of psychoeducation. The calculation indicated a sample of 218 subjects as adequate for the purpose of detecting the hypothesized effect.

Inclusion criteria:

  • Age between 45 and 85 years;
  • Confirmed diagnosis of cardiovascular disease;
  • Presence of chronic cardiovascular disease;
  • Absence of cognitive impairment or mild/moderate cognitive impairment (Mini Mental Score >26);
  • Patient who has given informed consent personally or through Legal Representative.

Exclusion Criteria:

  • Presence of severe psychiatric and neurological disorders.
  • Presence of end-stage oncological disease.
  • Severe visual impairment that cannot be corrected by dioptric lenses.

Each patient who is eligible for this study will be presented with the purpose of the study and will freely decide whether to join. Only after the patient, or his/her Legal Representative, has agreed to participate in the investigation and signed the informed consent, can the Investigator proceed with the planned activities, detailed below.

The patient's pathway should unfold as follows:

Each patient's clinical data will be shared from a database, accessible to study collaborators through previously assigned login credentials. After checking inclusion and exclusion criteria and signing informed consents, patients will be taken on.

  1. Baseline Examination.

    • Verification of inclusion and exclusion criteria;
    • Collection of demographic data;
    • Collection of the patient's clinical history;
    • Collection of information about the history of specific pathology and comorbidities.

    Thereafter, standardized tests for psychological, neuropsychological and associated clinical conditions will be administered. In addition, there will be at least one psychoeducation meeting that can also be conducted in groups. The following tests will be administered:

    • SF 36 Questionnaire or SF 12 Questionnaire;
    • MaugerI CaRdiac preventiOn-Questionnaire (MICRO-Q);
    • Mini-mental state examnation (MMSE);
    • Beck's Depression Inventory (BDI);
    • Beck's Anxiety Inventory (BAI);
    • Zarit Burden Inventory (ZBI);
    • Eat-10 test for monitoring swallowing ability and/or Swallowing Disturbance Questionnaire (SDQ).
    • STOPBANG questionnaire and/or 2ABN3M score;
    • Voice assessment using GIRBAS Scale and VHI. Feasibility will be assessed by considering adherence to the monitoring program through testicular assessments that will be performed not only at the baseline visit (T0) but also at the six-month follow-up (T1).
  2. Follow-up visit. For each patient, the assessment tests will be repeated at the same time as the periodic follow-up visits.
02

Conditions studied

  • Cardiovascular Disease

Keywords

  • Cardiovascular disease
  • neuropsychological
  • depression
  • anxiety
  • psychoeducation
  • dysphagia
  • caregiver
  • sleep disorders
  • altered pneumophonic coordination
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 218 is below the median of 534 across 1,577 observational studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

IRCCS Centro Neurolesi Bonino Pulejo is the lead sponsor of 67 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 85 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

A minimum of 218 patients recruited from those afferent at the U.O.S.D. Cardiology with NICU P.O. "Piemonte" in Messina will participate in the survey. Statistical power analysis was performed using G*Power software for a linear regression test, assuming a slope (H1) of 0.2 with a significance level (α) of 0.05 and a power (1 - β) of 0.85. The primary outcome variable considered for the calculation was the result of the SF-12 (or SF-36) test as a summary index of the effectiveness of psychoeducation. The calculation indicated a sample of 218 subjects as adequate for the purpose of detecting the hypothesized effect

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 45 and 85 years;

    • Confirmed diagnosis of cardiovascular disease;
    • Presence of chronic cardiovascular disease;
    • Absence of cognitive impairment or mild/moderate cognitive impairment (Mini Mental Score >26);
    • Patient who has given personally or through Legal Representative

Exclusion criteria

Exclusion Criteria:

    • Presence of severe psychiatric and neurological disorders
  • Presence of end-stage oncological disease.
  • Severe visual impairment that cannot be corrected by dioptric lenses
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
218 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. effectiveness of psychoeducation

    The primary outcome variable considered for calculation is the result of the SF-12 (or SF-36) test as a summary index of the effectiveness of psychoeducation.

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for May 2026, 24 months after the start.

Of 583 non-industry observational studies under Cardiovascular Diseases, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 196. This study's planned 24 months is below that.

Counting every sponsor, half of 667 studies reached it within 62 months; a quarter within 24 and three quarters within 192.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2024
First posted
May 14, 2024
StartActual
May 9, 2024
Primary completionEst.
May 13, 2026
CompletionEst.
May 13, 2026
Last update
May 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06413823
Lead sponsor
IRCCS Centro Neurolesi Bonino Pulejo
Responsible party
Irene Cappadona (Psychologist, IRCCS Centro Neurolesi Bonino Pulejo) — Principal investigator
First posted
May 14, 2024
Start date
May 9, 2024
Primary completion
May 13, 2026 (estimated)
Completion
May 13, 2026 (estimated)
Last update
May 14, 2024

Study contacts

Irene Cappadona, psychologist
Contact
irene.cappadona@irccsme.it
3274409990
Irene Cappadona
Contact
irene.cappadona@irccsme.it
3274409990
Irene Cappadona
principal investigator · IRCCS Centro Neurolesi Bonino Pulejo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion